Windsor Regional Hospital Approved To Provide COVID-19 Monoclonal Antibody And Anti-Viral Medication
Hello time traveller!!
This article is 305 days old.
The information listed below is likely outdated and has been preserved for archival purposes.
Windsor Regional Hospital has been approved to provide COVID-19 medications of monoclonal antibody and anti-viral medication to treat COVID-19 for positive patients who meet very specific criteria established by the Ontario COVID-19 Science Advisory Table.
Paxlovid is a pill form anti-vital treatment for high risk patients with mild to moderate COVID-19 symptoms, while Sotrovimab is an antibody infusion (IV) treatment for COVID-19 patients with mild to moderate COVID-19 symptoms. Both are among the treatments that have been approved by Health Canada. There is currently a limited supply of both medications.
If you fall under any of the categories below you may qualify for either Monoclonal Antibody Treatment or Antiviral Treatment for Covid-19:
- immunocompromised individuals aged 18 and over regardless of vaccine status
- unvaccinated individuals aged 60 and over
- unvaccinated First Nation, Inuit and Métis individuals aged 50 and over
- unvaccinated individuals aged 50 and over with one or more risk factors
Paxlovid anti-viral treatment Treatment with Paxlovid must begin within five days of symptom onset to be effective. A full course of treatment is three pills twice daily for five days in a row.
The hospital stresses that Paxlovid is not a replacement for vaccination. This anti-viral treatment is intended for those who are at higher risk of severe outcomes that may lead to hospitalization.
Find full details on the hospitals website.
